A National Registry on Chinese Patients With Lymphangioleiomyomatosis
ConditionPulmonary Function
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorPeking Union Medical College Hospital
About this trial
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.
Eligibility criteria
Qualifiers
Gender: female.
Age: no limitation.
Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of LAM based on ATS/JRS and ERS criteria. (2) Investigators recommend including of the patient.
Disqualifiers
Suspected LAM patients without other supporting evidence for LAM diagnosis.
No diffuse cystic lesions in the lung.
Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be established.
Without signed informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Peking Union Medical College Hospital
Lead sponsor
Shanghai Zhongshan Hospital
Collaborator
Guangzhou Institute of Respiratory Disease
Collaborator
Central South University
Collaborator
Anhui Provincial Hospital
Collaborator
Xiangya Hospital of Central South University
Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborator
Wuxi People's Hospital
Collaborator
Beijing Shijitan Hospital, Capital Medical University
Collaborator
West China Hospital
Collaborator
Fujian Provincial Hospital
Collaborator
Wuhan TongJi Hospital
Collaborator
Source ClinicalTrials.gov